Alx Oncology Holdings (ALXO) Non-Current Debt (2019 - 2026)

Alx Oncology Holdings' Non-Current Debt history runs 8 years deep, the most recent figure standing at $3.3 million for Q1 2026.

• In Q1 2026, Non-Current Debt fell 59.97% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $3.3 million (down 59.97% YoY), while the FY2025 annual figure was $4.5 million, down 52.14% from the prior year.
• Non-Current Debt came in at $3.3 million for Q1 2026 at Alx Oncology Holdings, down from $4.5 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $9.8 million in Q3 2024 to a low of $2.5 million in Q2 2022.
• A 5-year average of $7.5 million and a median of $9.4 million in 2022 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt surged 570.64% in 2022 and slumped 59.97% in 2026, its largest moves.
• Alx Oncology Holdings' Non-Current Debt stood at $9.4 million in 2022, then advanced by 2.66% to $9.6 million in 2023, then retreated by 1.76% to $9.5 million in 2024, then slumped by 52.14% to $4.5 million in 2025, then declined by 27.29% to $3.3 million in 2026.
• According to Business Quant data, Non-Current Debt over the past three periods registered $3.3 million, $4.5 million, and $5.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison